Morinaga Milk Industry Co., Ltd.

The Green Cross Corporation

The Salk Institute for Biological Studies

Ludwig Institute for Cancer Research Limited

Sloan-kettering Institute for Cancer Research

Other

Fumimaro Takaku

Ronald Mark Evans

Takashi Ishikawa

Kazuhiko Umesono

Michio Imawari

Nobuya Yanai

Carl-Henrik Heldin

Kohei Miyazono

Muneo Yamada

Katsuhiro Ogasa

Morio Kuboyama

Ulf G Hellman

Christer Wernstedt

Fuyuki Ishikawa

Kazuo Motoyoshi

Nobuhiro Yamada

Masayuki Nishida

Minoru Saito

Takuji Kawashima

Hajime Yokota

Shinya Suzu

Katsuo Yoshida

Kunio Ujiie

Yoshiteru Watanabe

A novel gamma retinoic acid receptor is disclosed. The novel receptor is encoded for by cDNA carried on plasmid pGEM-hRAR&#x3b3;, which has been deposited with the American Type Culture Collection for patent purposes. Chimeric receptor proteins are also disclosed. The chimera contain at least one functional domain from the new gamma retinoic acid receptor.

Nucleic acid encoding gamma retinoic acid receptor fusion protein

A novel gamma retinoic acid receptor is disclosed. The novel receptor is encoded for by cDNA carried on plasmid pGEM-hRAR&ggr;, which has been deposited with the American Type Culture Collection for patent purposes. Chimeric receptor proteins are also disclosed. The chimera contain at least one functional domain from the new gamma retinoic acid receptor.

Gamma retinoic acid receptor

Platelet-derived endothelial cell growth factor (PD-ECGF) is a 45 kDa endothelial cell mitogen that has been purified to homogeneity from human platelets. It does not bind to heparin and does not stimulate the proliferation of fibroblasts, in contrast to other endothelial mitogens of the fibroblast growth factor (FGF) family. PD-ECGF appears to be the only endothelial cell growth factor in human platelets and recent data indicate that it has angiogenic activity in vitro, i.e., the ability to stimulate the formation of new blood vessels and chemotactic activity, in vitro. The present invention provides a homogeneous PD-ECGF in substantially greater yields than available in the past, the primary structure of PD-ECGF, antibodies against PD-ECGF, clones of its cDNA, and variants thereof. The invention also provides a therapeutic preparation of PD-ECGF.

Peptides derived from endothelial cell growth factor

A novel gamma retinoic acid receptor is disclosed. The novel receptor is encoded for by cDNA carried on plasmid pGEM-hRAR.gamma., which has been deposited with the American Type Culture Collection for patent purposes. Chimeric receptor proteins are also disclosed. The chimera contain at least one functional domain from the new gamma retinoic acid receptor.

Human M-CSF preparations and recombinant human M-CSF preparations against myelodysplastic syndrome, malignant tumor and hyperlipemia and auxiliary therapeutic preparations to be dosed along with platinum-complex anticancer preparations.

Human monocyte-macrophage-CSF preparations

Human gamma retinoic acid receptor DNA

DNA encoding platelet derived endothelial cell growth factor (PD-ECGF)

A therapeutic agent for thrombocytopenia due to hemopoietic disorder induced by various causes comprises as an active ingredient a specific human monocytemacrophage colony stimulating factor. It is administered for the treatment and/or prevention of such thrombocytopenia.

M-CSF as a therapeutic agent for thrombocytopenia

A colony stimulating factor effective in treating human granulocytopenia is produced by cultivating monocytes and macrophages isolated from the human peripheral blood in a synthetic medium for tissue culture containing a glycoprotein isolated from human urine and capable of stimulating the formation of human granulocytes or mouse macrophages and granulocytes.

Method for producing substance capable of stimulating differentiation

A colony-stimulating factor having definite physical and chemical properties and a function of stimulating activity on human bone marrow cells to proliferate and differentiate, thereby forming granulocyte colonies, is obtained from human urine by concentrating the urine with respect to proteins contained therein by adsorption chromatography with silica gel, salting out with ammonium sulfate and other means, then removing impurities by adsorption on cation exchanger, and further purifying by ion exchanging chromatography on anion exchanger, gel filtrating chromatography with highly crosslinked gels, affinitive chromatography with sugar affinitire adsorbents and electrophoresis.

HGI-Glycoprotein capable of stimulating proliferation and

Growing community of inventors

Tokyo, Japan

Fumimaro Takaku